ATE119396T1 - Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin. - Google Patents

Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin.

Info

Publication number
ATE119396T1
ATE119396T1 AT89311297T AT89311297T ATE119396T1 AT E119396 T1 ATE119396 T1 AT E119396T1 AT 89311297 T AT89311297 T AT 89311297T AT 89311297 T AT89311297 T AT 89311297T AT E119396 T1 ATE119396 T1 AT E119396T1
Authority
AT
Austria
Prior art keywords
inhibin
activin
treatment
beta
globin
Prior art date
Application number
AT89311297T
Other languages
English (en)
Inventor
Susan P Perrine
Norbert Albers
Original Assignee
Susan P Perrine
Norbert Albers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Susan P Perrine, Norbert Albers filed Critical Susan P Perrine
Application granted granted Critical
Publication of ATE119396T1 publication Critical patent/ATE119396T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT89311297T 1988-11-01 1989-11-01 Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin. ATE119396T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/266,421 US4997815A (en) 1988-11-01 1988-11-01 Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin

Publications (1)

Publication Number Publication Date
ATE119396T1 true ATE119396T1 (de) 1995-03-15

Family

ID=23014518

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89311297T ATE119396T1 (de) 1988-11-01 1989-11-01 Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin.

Country Status (9)

Country Link
US (1) US4997815A (de)
EP (2) EP0617966A1 (de)
JP (1) JPH02256622A (de)
AT (1) ATE119396T1 (de)
CA (1) CA2001897A1 (de)
DE (1) DE68921546T2 (de)
IL (1) IL92167A (de)
MA (1) MA21667A1 (de)
PT (1) PT92174B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03173805A (ja) * 1989-09-11 1991-07-29 Ajinomoto Co Inc 卵分割促進剤
US5166190A (en) * 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
US5102868A (en) * 1990-01-08 1992-04-07 Genentech, Inc. Method for inhibiting follicular maturation
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof
WO1991012334A1 (en) * 1990-02-15 1991-08-22 Cetus Corporation Inhibitor of cytokine activity and applications thereof
WO1992004913A1 (en) * 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
USD354971S (en) 1993-07-26 1995-01-31 Mugnier Design Eyeglasses
EP0664699A1 (de) * 1993-08-13 1995-08-02 Vitaphore Corporation Arzneimittelabgabesystem auf der Basis von Hydrogelmikrokugeln
US5487895A (en) * 1993-08-13 1996-01-30 Vitaphore Corporation Method for forming controlled release polymeric substrate
CA2174737C (en) * 1993-10-29 2008-04-22 Douglas V. Faller Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
EP2298350A3 (de) 1996-07-26 2011-06-08 Susan P. Perrine Zusammensetzung enthaltend einen induzierenden wikstoff und einen antiviralen wirkstoff zur behandlung von viralen störungen
AUPO638897A0 (en) * 1997-04-23 1997-05-22 Monash University Modulation of cell growth and methods relating thereto
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
AU2012203441B2 (en) * 2002-05-17 2015-01-29 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
US20060003446A1 (en) * 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
EP1543110A4 (de) * 2002-05-17 2006-09-06 Sinai School Medicine Mesoderm- und definitive endoderm-zellpopulationen
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
CA2575370A1 (en) * 2004-08-10 2006-02-23 Voyager Pharmaceutical Corporation Methods for treating premature infants
EP1824831A2 (de) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2009501236A (ja) * 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
CN102802412A (zh) 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016064815A1 (en) * 2014-10-20 2016-04-28 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
EP3484489B1 (de) 2016-07-15 2025-06-18 Viracta Subsidiary, Inc. Hdac-hemmer zur verwendung mit therapien auf der basis von nk-zellen
CA3142142A1 (en) 2019-05-31 2020-12-03 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
CA3236051A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0730114B2 (ja) * 1985-04-03 1995-04-05 正雄 五十嵐 インヒビン
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
NZ231899A (en) * 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4822821A (en) * 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
EP0299050B1 (de) * 1987-01-29 1995-03-22 Biotechnology Australia Pty. Ltd. Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5032507A (en) * 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis

Also Published As

Publication number Publication date
PT92174A (pt) 1990-05-31
PT92174B (pt) 1995-09-12
EP0617966A1 (de) 1994-10-05
IL92167A0 (en) 1990-07-12
JPH02256622A (ja) 1990-10-17
EP0367590B1 (de) 1995-03-08
IL92167A (en) 1994-07-31
MA21667A1 (fr) 1990-07-01
US4997815A (en) 1991-03-05
EP0367590A3 (de) 1992-01-02
DE68921546D1 (de) 1995-04-13
CA2001897A1 (en) 1990-05-01
DE68921546T2 (de) 1995-07-06
EP0367590A2 (de) 1990-05-09

Similar Documents

Publication Publication Date Title
ATE119396T1 (de) Erhöhung des fetalen hämoglobins durch behandlung mit aktivin und/oder inhibin.
ATE130762T1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
ES2056854T3 (es) Tiadiazinonas.
DK0396184T3 (da) Anvendelse af ketoconazol og et retinoid til behandling af acne vulgaris
FR2721516B1 (fr) Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation.
EP0371789A3 (de) Arzneimittel zur Erhöhung des Gehaltes an fötalem Hämoglobin
ATE69550T1 (de) Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen.
BOWEN et al. A prospective study of stress ulceration in Vietnam
JPS51118841A (en) A drug for improving and treating clouding of consciousness
Schor et al. Rotating grating treatment of amblyopia with and without eccentric fixation
Whitley et al. Identification and management of psychosocial and environmental problems of children with cancer
Chandra Some aspects of tuberculous meningitis in Surabaya
SU588982A1 (ru) Способ лечени сахарного диабета
SU1169655A1 (ru) Способ лечени тромбооблитерирующих заболеваний артерий конечностей
Orege et al. Multidrug therapy for treatment of paucibacillary leprosy in western Kenya--preliminary communications
SU940377A1 (ru) Способ комплексного лечени звенной болезни желудка и двенадцатиперстной кишки
Mitchell Lead poisoning in children
Moon et al. Clinical Study of Kienbock's Disease
Bash Pernicious anemia in young black women
Berger et al. Changes in the Sydney line during the first year of life
TNSN90103A1 (fr) Procede pour augmenter l'hemoglobine foetale par traitement avec de l'activine et/ou de l'inhibine
Behrman et al. Alopecia Areata Due to Syphilis
DS Sexual dysfunctions in the male
Gugler Mercury and the'Pains of Love'in Jonathan Swift's' A Beautiful Young Nymph Going to Bed'
宋宝珠 et al. SHORT-TERM EFFECT IN 135 CASES OF ENURESIS TREATED BY WRIST-ANKLE NEEDLING